---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-237582"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:35:28.473179+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Atara Biotherapeutics appoints Eric Hyllengren as COO, retains CFO role

## Summary
- Eric Hyllengren appointed Chief Operating Officer effective Oct 14, 2024, while continuing as CFO.
- Salary increased to $520,000 per year in connection with the promotion.
- Hyllengren has been CFO since April 2023 and with Atara since 2018.

## SEC filing metadata
- accession: 0001193125-24-237582
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312524237582/0001193125-24-237582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312524237582/d729291d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-237582
- JSON: https://secwatch.observer/filing/0001193125-24-237582.json
- Plain text: https://secwatch.observer/filing/0001193125-24-237582.txt

## Key facts
- Executive change
  Eric Hyllengren was appointed as Chief Operating Officer at Atara Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On October 14, 2024, the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc. (the “Company”) appointed Eric Hyllengren to serve as the Company’s Chief Operating Officer, in addition to his role as the Company’s Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312524237582/0001193125-24-237582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.